Announcement PDF AGM PRESENTATION 21 NOVEMBER, 2023 S t e v e n Ly d e a m o r e - C E O NASDAQ: IMRN ASX: IMC 1 SAFE HARBOR STATEMENT C e rta in state m e nts ma de in this pre s e nta t io n a re fo rwa rd- lo o k i n g state m e nt s a nd a re ba s e d o n I mmuro n’s c urre nt ex pe c ta tio n s , e stimate s a nd pro j e c tio ns . Wo rds s uc h a s “a ntic ip a te s ,” “ex pe c ts ,” “inte n ds ,” “pla ns ,” “be lie ve s ,” “s e e ks ,” “e stima te s ,” “guida nc e ” a nd s imila r ex pre s s io ns a re inte n de d to ide nt if y fo rwa rd- lo o ki n g state me nt s . A ltho ug h I mmuro n be lie ve s the fo rwa rd- lo o k i n g state m e nts a re ba s e d o n re a s o na ble a s s umptio n s , the y a re s ubj e c t to c e rta in ris ks a nd unc e rta i nt ie s , s o me o f whic h a re be yo nd I mmuro n’s c o ntro l, inc ludi n g tho s e ris ks o r unc e rta i n ti e s inhe re nt in the pro c e s s o f bo th de ve lo pi n g a nd c o mme rc ia liz i n g te c hno lo g y. A s a re s ult, a c tua l re s ults c o uld mate ria l l y diffe r f ro m tho s e ex pre s s e d o r fo re c a ste d in the fo rwa rd- lo o k in g state me n ts . The fo rwa rd- lo o k i n g state m e nts ma de in this pre s e nta t io n re late o nly to e ve nts a s o f the date o n whic h the state m e nts a re ma de . I mmuro n will no t unde rta ke a ny o bligat io n to re le a s e public l y a ny re vis io ns o r upda te s to the s e fo rwa rd- lo o k i ng state me n ts to ref le c t e ve nts , c irc umsta nc e s o r una nt ic i p a te d e ve nts o c c urring a f te r the date o f this pre s e nta t io n exc e pt a s re quire d by la w o r by a ny a ppro pri a te re gula to r y a utho ri t y. F Y2024 re s ults in this pre s e nta t io n a re s ubj e c t to a udit re vie w. 2 EXECUTIVE SUMMARY Immuron Ltd (ASX:IMC) (NASDAQ:IMRN) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases Company Overview Business Update • Platform Technology: capable of producing highly specific orally active immunoglobulins to any enteric pathogen • Two commercially available oral immunotherapeutic products – Travelan® and Protectyn® • Three pipeline assets in four clinical programs • Market capitalisation of $16.86 million as of 17 November 2023 with cash and cash equivalates balance of $17.2 million as of 30 June 2023 • Global sales increased 136% in FY23 to $1.80 million; Travelan® sales of $1.74 million • Record quarterly Travelan® sales of $1.55 million in Q1, FY2024 • Travelan® is now the #2 SKU and fastest growing in the Antidiarrheal category across all pharmacy in Australia1 • Australian sales YTD FY24 have exceeded full year FY23 sales • Pursuing growth strategies to expand commercial product sales within existing and new geographies and to increase product offering • Launched on Amazon in USA in July 2023 • Status of investment in leading gut health biotech, Ateria Health • • Launched ground-breaking Juvia™ for irritable bowel syndrome (IBS) in UK (August 2022), Australia (July 2023) • September 2023: annualised revenue run rate >A$1.2 million with 40%+ growth trajectory since April 2023 Achieved milestones in all clinical programs (Travelan® IND, Travelan® USU study, CampETEC and IMM-529) ; near-term milestones anticipated 1. IQVIA Australia Pharmacy Scan – Antidiarrheal segment, value sales 13 weeks to 21 October 2023 3 COMPANY HIGHLIGHTS Strong Sales Growth o o Global sales increased by 136% in the 2023 fiscal year to A$1.80 million compared to A$0.77 million in FY22 Record quarterly global sales in Q1, FY24 of $1.57 million o Australia Net Sales o FY23: A$1.16 million o Q1, FY24: A$1.35 million o 229% higher than pre-pandemic period Q1, FY20 o 12 months to July 2023 short term resident returns 77% of those in 20191 o Travelan® is now the #2 SKU and fastest growing in the Antidiarrheal category across all pharmacy in Australia2 o Australian sales YTD FY24 have exceeded full year FY23 sales o USA Net Sales o FY23: A$0.64 million o Q1, FY24: A$0.21 million o 9% lower than pre-pandemic period Q1, FY20 o Total departures June 2023 99.4% of June 20193 1. https://www.abs.gov.au/statistics/industry/tourism-and-transport/overseas-arrivals-and-departures-australia/latest-release 2. IQVIA Australia Pharmacy Scan – Antidiarrheal segment, value sales 13 weeks to 21 October 2023 3. https://www.trade.gov/sites/default/files/2023-09/US-Outbound-to-World-Regions.xlsx 4 STRONG PIPELINE WITH NEAR TERM MILESTONES Immuron’s Clinical Programs Compound or brand name Indication IMM-124E Travelan® Traveler’s Diarrhea ETEC challenge IMM-529 Clostridioides difficile Infection & Recurrence Phase I Phase II Phase III Market Our Partners’ Clinical Programs Compound or brand name Travelan® CampETEC Partner Phase I Phase II Phase III Market Uniformed Services University Naval Medical Research Command 5 COMPANY HIGHLIGHTS Collaborations with U.S. DoD – Remain Strong o o o o o o o Travelan® IND Approval – December 2022 Study Initiation – May 2023 First cohort recruitment completed – July 2023 Presentations at Military Health System Research Symposium – August 2023 Second cohort recruitment completed – October 2023 Completion of In-patient phase – October 2023 Anticipated Top Line Results and Clinical Study Report – 1H 2024 US Uniformed Services University Traveller’s Diarrhoea Clinical Field Trial o o o o o USU’s Infectious Diseases Clinical Research Program (IDCRP), the UK Ministry of Defence and the New York City Travel Clinic are jointly planning to conduct the randomized clinical trial to evaluate the efficacy of Travelan® against placebo for Traveller’s Diarrhoea Florastor® removed from active study arms – February 2023 o Now 868 study participants (434 per arm) 50% recruitment milestone – October 2023 Anticipated completion of recruitment – March 2024 Anticipated completion of In-patient phase – June 2024 6 COMPANY HIGHLIGHTS US Naval Medical Research Command – Campylobacter & ETEC PROJECT o o o o o o New Therapeutic in Clinical Development for Treatment of moderate to severe Campylobacteriosis and Infectious diarrhea caused by ETEC pathogens Toxicology study completed – December 2022 FDA removed IND Clinical Hold – May 2023 Institutional Review Board Approval – October 2023 Anticipated Initiation of Campylobacter Controlled Human Infection Model (CHIM) clinical trial – 1H2024 Anticipated completion of In-patient phase – 1H2024 7 COMPANY HIGHLIGHTS IMM-529 Clinical Development for Treatment of C. difficile Infections o o o o o o o o o Opportunity Assessment Completed C. difficile infection (CDI) affects just over ~400,000 people in the US annually Sizable number of patients who experience at least one recurrence (~20-25%), Many patients experience multiple recurrences, creating persistent unmet need for novel therapies to address recurrences Infectious disease experts reacted favorably to the IMM-529 MOA, and its ability to target three elements of the rCDI infection –the spores, vegetative cells, and Toxin B. Non-antibiotic treatments (such as IMM-529) are appealing to experts 600mg solid dose active formulation development – February 2023 Anticipated cGMP manufacture – December 2023 Anticipated FDA pre-IND submission – 1H 2024 8 STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION: EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +613 8892 4854 9 SCIENTIFIC REFERENCES Travelan® (IMM-124E) Travelan® has been shown to reduce both the incidence and severity of ETEC-induced diarrhea in up to 90% of volunteers Scandinavian Journal of Gastroenterology, 46:7-8, 862-868, DOI: 10.3109/00365521.2011.574726 Clinical Evaluation of Travelan® an Oral Prophylactic for Prevention of Travelers’ Diarrhea in Active Duty Military Service Assigned Abroad. Military Health System Research Symposium 14-17 Aug 2023_Abstract 1 Travelan as a broad Spectrum anti-bacterial Immuron Limited, 29 April, 2011 Travelan® demonstrates broad reactivity to Vibrio cholera strains from Southeast Asia indicating broad potential for prevention of traveler’s diarrhea US Department of Defense, Armed Forces Research Institute of Medical Sciences (AFRIM), 4 September, 2019 Travelan® prevented clinical shigellosis (bacillary dysentery) in 75% of Travelan® treated animals compared to placebo and demonstrated a significant clinical benefit US Department of Defense, Armed Forces Research Institute of Medical Sciences (AFRIM), 5 September, 2018 Travelan® able to bind and was reactive to 60 clinical isolates of each bacteria, Campylobacter, ETEC, and Shigella US Department of Defense, Armed Forces Research Institute of Medical Sciences (AFRIM), 30 January, 2017 Efficacy of hyperimmune bovine colostrum against shigellosis in rhesus macaque (Macaca mulatta), and bioactivity of HBC against common enteric pathogens Islam et al., 2020. Submitted to mSphere, American Society for Microbiology Bioactive Immune Components of Travelan® Clin Vaccine Immunol 24:e00186-16. https://doi.org/10.1128/CVI.00186-16 Hyperimmune bovine colostrum containing lipopolysaccharide antibodies (IMM-124E) has a non-detrimental effect on gut microbial communities in unchallenged mice Rachele Gore, Mitra Mohsenipour, Jennifer L Wood, Gayathri K Balasuriya, Elisa L Hill-Yardin, Ashley E Franks Administration of the Hyper-immune Bovine Colostrum Extract IMM-124E Ameliorates Experimental Murine Colitis Journal of Crohn's and Colitis, Volume 13, Issue 6, June 2019, Pages 785–797, https://doi.org/10.1093/ecco-jcc/jjy213 IMM-529 Bovine antibodies targeting primary and recurrent Clostridium difficile disease are a potent antibiotic alternative Sci Rep 7, 3665 (2017). https://doi.org/10.1038/s41598-017-03982-5 10